Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases

J Clin Pharmacol. 2010 Jun;50(6):714-20. doi: 10.1177/0091270009353031. Epub 2010 Jan 26.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / metabolism*
  • Antidepressive Agents, Second-Generation / pharmacokinetics*
  • Aryl Hydrocarbon Hydroxylases / metabolism*
  • Bupropion / analogs & derivatives*
  • Bupropion / pharmacokinetics*
  • Chronic Disease
  • Cytochrome P-450 CYP2B6
  • Female
  • Humans
  • Lupus Nephritis / metabolism*
  • Male
  • Middle Aged
  • Oxidoreductases, N-Demethylating / metabolism*
  • Phenotype
  • Stereoisomerism

Substances

  • Antidepressive Agents, Second-Generation
  • Bupropion
  • Aryl Hydrocarbon Hydroxylases
  • CYP2B6 protein, human
  • Cytochrome P-450 CYP2B6
  • Oxidoreductases, N-Demethylating
  • radafaxine